iwAL MRD working group session
Chairs: Naval Daver & Andrew Wei

 

Part 1: Prognostic implications

• Flow cytometry: Sanam Loghavi
• NPM1: Jad Othman
• FLT3: Christopher Hourigan

 

Part 2: Endpoints for clinical trials: Michael Heuser

 

Part 3: MRD-directed therapies

• Talk title TBC: Andrew Wei
• Talk title TBC: Naval Daver

 

Part 4: FDA perspective: TBC

 

Part 5: Panel discussion

Welcome & introduction
Naval Daver

Session 1: Translational and lab developments and applications in AML
Chairs: Ravindra Majeti & Ioannis Aifantis

• Talk title TBC: Ann-Kathrin Eisfeld
• Clonal evolution of therapy-related myeloid neoplasms: Koichi Takahashi
• Talk title TBC (venetoclax + gilteritinib): Catherine Smith

Panel discussion

Session 2: New science implications for AML
Chairs: Koichi Takahashi & Paresh Vyas

• Talk title TBC: Ravindra Majeti
• Talk title TBC: Ioannis Aifantis
• Talk title TBC: TBC

Panel discussion

Session 3: Transplantation in AML
Chairs: Courtney DiNardo & Eytan Stein

• GVL new approaches: Paresh Vyas
• IC+VEN in newly diagnosed fit AML – Who are the optimal patients for this approach?: Courtney DiNardo
• Strategies to optimise transplant outcomes: Charles Craddock
• Debate: Is pre-transplant intervention warranted in patients with MRD+ AML CR1?
  • Yes: Maximilian Stahl
  • No: Roland Walter

Panel discussion

Day 1 conclusions
Naval Daver

Welcome to Day 2
Naval Daver

Session 4: Updates on established therapies in AML
Chairs: Jessica Altman & Andrew Wei

• Intensive or non-intensive induction: Curtis Lachowiez
• Optimal approach to treatment of secondary/therapy-related AML: Tara Lin
• Improving induction strategies: Tapan Kadia
• Venetoclax de-escalation: Stéphane de Botton

Panel discussion

Session 5: Immunotherapies in AML
Chairs: Marion Subklewe & Roland Walter

• Early-phase CAR and γδ T cell immunotherapy trials for R/R AML and MDS: Nelli Bejanyan
• NK cell-based therapies in AML: Jeffrey Miller
• Talk title TBC: Marion Subklewe
• Talk title TBC: John DiPersio

Panel discussion

Break

Session 6: Targeting FLT3-mutant AML
Chairs: Richard Stone & Amir Fathi

• Frontline approaches for FLT3-mutant AML: Naval Daver
• Current approaches and challenges for relapsed FLT3-mutant AML: Jessica Altman
• Mechanisms of resistance to FLT3 inhibitors and how we can overcome them: Alexander Perl
• Designing and applying a FLT3-like signature in AML: Adrián Mosquera Orgueira

Panel discussion

Session 7: International trials group
Chairs: Naval Daver & Charles Craddock

• UK trials: Charles Craddock
• US trials: Harry Erba
• SAL trials: Christoph Röllig
• French trials: TBC

Panel discussion

Lunch

Session 8: Value and utility of MRD in the management of adults with newly-diagnosed AML
Chairs: Mark Levis & Farhad Ravandi

• Debate: MRD technology is an expensive luxury in the management of the majority of fit adults with newly-diagnosed AML
  • For: MRD technology is an expensive luxury and not valuable for the majority of fit adults with newly-diagnosed AML:
    Harry Erba & Eunice Wang
  • Against: MRD technology is valuable in treatment decision-making and should be included in all fit patients with newly-diagnosed AML:
    Sanam Loghavi & Roland Walters

Panel discussion

Keynote talk 1
Talk title TBC: Gail Roboz

 

Break

Session 9: New frontiers in MRD for AML: Regulatory perspective and clinical practice
Chairs: Naval Daver, Gail Roboz & TBC

• Cell-free DNA MRD: Tian Yi Zhang
• MRD as a clinical endpoint in clinical trials: Nicholas Short
• Talk title TBC: TBC

Panel discussion

Session 10: Clonal hematopoiesis, BPDCN & CMML
Chairs: Naveen Pemmaraju & Andrew Lane

• Updates in diagnosis, pathogenesis, and future directions in BPDCN: Naveen Pemmaraju
• Talk title TBC: Andrew Lane
• Potential for early intervention in CHIP and CCUS: Updates and ongoing trials: Uma Borate
• Future targets and trials progress in CMML: Guillermo Montalbán Bravo

Panel discussion

Day 2 conclusions

Welcome to Day 3

Keynote talk 2
Talk title TBC: Charles Craddock

Session 11: Menin inhibition in AML
Chairs: Naval Daver & Andrew Wei

• Single-agent menin inhibitors – efficacy, biomarkers and resistance: Ghayas Issa
• Menin inhibitor combinations: Joshua Zeidner
• Venetoclax or menin inhibitors for NPM1-mutated AML: Eytan Stein
• Mechanisms of resistance to menin inhibitors: Amir Fathi

Panel discussion

Session 12: TP53-mutated AML
Chairs: David Sallman & Eunice Wang

• Biological insights: Andrew Wei
• Management in 2025: Justin Watts
• Future approaches: David Sallman
• Tuspetinib for relapsed or refractory AML: Gabriel Mannis

Panel discussion

Break

Session 13: Novel targets, combinations and treatments in AML (part I)
Chairs: Tapan Kadia & Harry Erba

• Overcoming resistance to venetoclax-based therapies in AML: Harry Erba
• Promising combination options with AZA/VEN for R/R AML: Thomas Cluzeau
• Talk title TBC: Hima Atluri

Panel discussion

Session 14: Novel targets, combinations and treatments in AML (part II)
Chairs: Farhad Ravandi & Gail Roboz

• Optimal use of OGM and RNA translocation panel in frontline AML: Sanam Loghavi
• Novel ADCs in AML – how best to incorporate and use them: Farhad Ravandi
• Talk title TBC: Aditi Shastri

Panel discussion

Meeting summary and close
Naval Daver